HITF (Healthcare Industries Task Force): the end of a new beginning for UK medical technology
This article was originally published in Clinica
It is impossible in a brief summary to do justice to a strategy that seeks to re-steer and energise the £6bn ($11.2bn) machine that is the UK's medical technology industry. But last week's publication of the HITF report is actually just the end of the beginning - the nuts and bolts of a nine-part system designed by around 200 people over the last year to improve the machine's performance. That design is now ready to be engineered into the current R&D, manufacturing, marketing, healthcare delivery and regulatory systems, reports Bernard Murphy
You may also be interested in...
Inovio forges ahead into Phase I trials with DNA-based vaccine candidate, but can it prove skeptics wrong?
Erectile dysfunction drug sildenafil, plus treatments for skin conditions such as eczema, are among a bounty of Rx-to-OTC switches approved in Switzerland.
Sandoz has appointed a new leader for its Japanese business following the acquisition of Aspen’s local operations, while Stada has brought in a former Sandoz and Pfizer executive to lead its Ciclum Farma unit in Portugal. Meanwhile, Julphar has a new CEO.